VC Lightstone has $250 million in the bank for life science research.
Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned ADCs.
RBM is, above all, an opportunity to practice mindfulness in collecting clinical trial data within the site- and patient-centric environment.
Arcus has signed a deal with Taiho that provides a healthy cash injection while keeping rights in the U.S. and other markets in hand.
XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million.
The clean sweep is a big win for Alnylam and the Sanofi-partnered RNAi drug, which is now set to be put before regulators at the end of the year.
Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.
Acceleron's collaboration with Celgene on sotatercept has taken another turn, giving Acceleron the right to develop the drug for pulmonary diseases.
Disarm Therapeutics has seen a strong $30 million series A round as it looks for a breakthrough approach in axonal degeneration.
Ultragenyx is putting up $138 million in cash to wrestle gene therapy biotech Dimension away from its first suitor.
Lefamulin held its own against established treatment moxifloxacin, raising hopes that Nabriva can establish it as a first-line treatment of CABP.